ADVERTISEMENT

Ralph J. Riello, III, PharmD, BCPS

Yale-New Haven Health System Designates Tirofiban as the Primary Glycoprotein IIb/IIIa Inhibitor

04/26/2017

Samuel S. Hahn , MD, FACC, FSCAI;

Ralph J. Riello III, PharmD, BCPS;

Given the therapeutic equivalence, we have saved approximately $125K in the past 12 months by switching to tirofiban just at Yale-New Haven Hospital. The savings system-wide are even higher.

Given the therapeutic equivalence, we have saved approximately $125K in the past 12 months by switching to tirofiban just at Yale-New Haven Hospital. The savings system-wide are even higher.

Given the therapeutic...

04/26/2017

Cath Lab Digest

Comparing Antiplatelet Therapy in STEMI: The FABOLUS-FASTER Trial

09/07/2020

Marco Valgimigli , MD, PhD, FESC;

Ralph J. Riello III, PharmD, BCPS;

The big surprise from the study is that the non-inferiority of cangrelor versus tirofiban was not met. Tirofiban was clearly superior to cangrelor. Among the 4 regimens, the mean level of platelet inhibition that can be achieved at 30 minutes...

The big surprise from the study is that the non-inferiority of cangrelor versus tirofiban was not met. Tirofiban was clearly superior to cangrelor. Among the 4 regimens, the mean level of platelet inhibition that can be achieved at 30 minutes...

The big surprise from the study...

09/07/2020

Cath Lab Digest

Featured Webinar

Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications

Advertisement

Advertisement

Advertisement

Upcoming Events

Dermatology Week

November 13 ⁠–⁠ November 16

Derm Week

November 13 ⁠–⁠ November 16

November 23 ⁠–⁠ November 24

December 4 ⁠–⁠ December 5

Great Debates & Updates in Diabetic Foot

December 6 ⁠–⁠ December 7

December 9 ⁠–⁠ December 11

December 9 ⁠–⁠ December 11

December 12 ⁠–⁠ December 13

December 14 ⁠–⁠ December 15

February 2 ⁠–⁠ February 5

See Full Calendar

Advertisement

Advertisement